Drug Trial Radar · NCT01091428
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jun 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
191
Actual
Start
Apr 16, 2010
Primary completion
Aug 12, 2014
Study completion Jul 19, 2017
Sponsor
- Lead sponsor
- Millennium Pharmaceuticals, Inc.Takeda (TAK)
- Sponsor type
- Industry
- First posted
- Mar 24, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter study with a nonrandomized Phase 1 portion and an open-label, randomized, Phase 2 portion evaluating MLN8237 in combination with weekly paclitaxel in adult female participants with advanced breast cancer (Phase 1 portion only) and recurrent ovarian cancer (both Phase 1 and Phase 2 portions).
Conditions
- Ovarian Carcinoma
- Fallopian Tube Cancer
- Peritoneal Cancer
- Breast Carcinoma
Interventions
AlisertibDrug
Alisertib tablets
PaclitaxelDrug
Paclitaxel intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With PaclitaxelTime frame: Cycle 1 (Up to 28 days)
- Phase 1: MTD and RP2D for Paclitaxel in Combination With AlisertibTime frame: Cycle 1 (Up to 28 days)
- Phase 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: First dose to 30 days past last dose (Up to 36 Months)
- Phase 1: Number of Participants With Clinically Significant Laboratory ValuesTime frame: First dose to 30 days past last dose (Up to 36 Months)
- Phase 1: Number of Participants With Clinically Significant Vital Sign FindingsTime frame: First dose to 30 days past last dose (Up to 36 Months)
- Phase 1: Number of Participants With Hypersensitivity and NeurotoxicityTime frame: Baseline up to Month 36
- Phase 2: Progression-Free Survival (PFS)Time frame: At the end of Cycle 2 and at the completion of every 2 cycles until PD was documented or up to data cut-off: 12 August 2014 (approximately 24 months)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Site not named
The Bronx, New York
Site not named
Philadelphia, Pennsylvania
Site not named
Houston, Texas
Site not named
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.